Cprx stock forecast.

Catalyst Pharmaceuticals earnings beat by $0.11, revenue topped estimates. Investing.com - Catalyst Pharmaceuticals (NASDAQ: CPRX) reported first quarter EPS of $0.310, $0.11 better than the analyst estimate of $0.200. Revenue for the quarter came in at $60.76M... Mar 15, 2023 20:18.Aug 30, 2023 · Looking at Catalyst's most recent earnings report, product revenues saw a significant increase of 87.5% YoY, rising to $99.5M in Q2 2023 from $53.0M in Q2 2022. While research and development ... For Catalyst Pharmaceuticals Stock (CPRX) price forecast for 2024, the average price target for Catalyst Pharmaceuticals Stock is $17.29 with a high forecast of $22.19 and a low forecast of $12.39. The average CPRX price prediction of 2024 represents a +31.36% increase from the last price of $13.16.View the latest Catalyst Pharmaceuticals Inc. (CPRX) stock price, news, historical charts, analyst ratings and financial information from WSJ.

The average Devon Energy stock price prediction forecasts a potential upside of 30.16% from the current DVN share price of $44.88. What is DVN's forecast return on equity (ROE) for 2023-2026? (NYSE: DVN) forecast ROE is N/A, which is considered weak.

Stock Price Forecast. The 7 analysts offering 12-month price forecasts for VNET Group Inc have a median target of 4.33, with a high estimate of 8.12 and a low estimate of 2.59. The median estimate ...May 11, 2023 · The midpoint of the outlook came in a hair below CPRX stock analyst forecasts for $381.5 million. But McEnany says the company is still on the lookout for new deals to bolster its sales.

2 Wall Street research analysts have issued 1-year price targets for WeWork's stock. Their WE share price targets range from $8.00 to $120.00. On average, they anticipate the company's stock price to reach $66.00 in the next year. This suggests a possible upside of 4,717.5% from the stock's current price.The current average CPRX price target, as estimated by these analysts, is $19.38. The predictions for the future CPRX stock price range from a low of $15.50 to a high of …Top Analysts Based on 3 analyst s offering 12 month price targets for Catalyst Pharmaceuticals Inc. Min Forecast $24.00 +68.9% Avg Forecast $25.00 +75.93% Max …Dec 1, 2023 · Catalyst Pharmaceuticals last released its quarterly earnings data on November 8th, 2023. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, hitting the consensus estimate of ($0.26). The business earned $102.69 million during the quarter, compared to the consensus estimate of $100.17 million.

Catalyst Pharmaceuticals (CPRX) is a biopharmaceutical company that develops and commercializes therapies for rare diseases. The company's stock price, news, and analysis are based on its market cap, P/E ratio, dividend yield, and earnings growth. The consensus rating is Buy, with a price target of $24.75, an upside of 95.8%.

Find out why CPRX stock is a Hold. ... During Catalyst's Q4, 2022 earnings call (the "Call") CEO McEnany forecast its 2023 revenues in a $245-$255 million range.

Q1 net revenues were $27.8 million for the approximately two months that we owned the U.S. rights to the product, which adds further confidence towards achieving our FYCOMPA full year 2023 net ...REAL Stock 12 Months Forecast. $4.25. (101.90% Upside) Based on 3 Wall Street analysts offering 12 month price targets for RealReal in the last 3 months. The average price target is $4.25 with a high forecast of $6.00 and a low forecast of $3.25. The average price target represents a 101.90% change from the last price of $2.11.Nov 26, 2023 · Catalyst Pharmaceuticals, Inc. (CPRX) share price prediction for 2023, 2024, 2025, 2026 and 2027. CPRX one year forecast. Catalyst Pharmaceuticals stock monthly and ... Devon Energy Corp Stock Forecast, Predictions & Price Target. Add to Watchlist. Overview Forecast. Earnings Dividend Ownership. Analyst price target for DVN. All Analysts Top Analysts. Based on 12 analysts offering 12 month price targets for Devon Energy Corp. Min Forecast. $48.00 +6.95%. Avg Forecast. $58.42 +30.16%.Cutting-Edge Science. The innovation behind a breakthrough. Our company is committed to developing novel, safe, and efficacious therapies to improve the lives of people with rare diseases.Find real-time KPRX - Kiora Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business.Find real-time VOD - Vodafone Group PLC stock quotes, company profile, ... EPS forecast (this quarter) $0.55: Annual revenue (last year) $47.5B: Annual profit (last year) $12.3B:

Nov 30, 2023 · Stock Price Forecast. According to 4 stock analysts, the average 12-month stock price forecast for CPRX stock stock is $23.75, which predicts an increase of 64.59%. The lowest target is $20 and the highest is $27. On average, analysts rate CPRX stock stock as a strong buy. Their TEVA share price targets range from $10.00 to $14.00. On average, they predict the company's stock price to reach $12.40 in the next year. This suggests a possible upside of 26.3% from the stock's current price. View analysts price targets for TEVA or view top-rated stocks among Wall Street analysts.... stock price performance. 48. Table of Contents. Market Information. Our common stock trades on the Nasdaq Capital Market under the symbol “CPRX.” The closing ...Aug 23, 2022 · 1. Catalyst Pharmaceuticals. Catalyst Pharmaceuticals ( CPRX 1.44%) is crushing Tesla stock because it's in the process of cornering a rare disease market that'll be worth hundreds of millions of ... The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics. Nov 21 / Zacks.com - Paid Partner Content. 2 Revolutionary Stocks That Could ...

30 cze 2023 ... Despite posting remarkable results, the company did not meet analyst expectations, leading to a fall in its stock price. CPRX shares have ...

For Catalyst Pharmaceuticals Stock (CPRX) price forecast for 2024, the average price target for Catalyst Pharmaceuticals Stock is $17.29 with a high forecast of $22.19 and a low forecast of $12.39. The average CPRX price prediction of 2024 represents a +31.36% increase from the last price of $13.16. $ 13.68 -0.13 -0.94% After Hours Volume: 104.52K Advanced Charting Volume: 1.17M 65 Day Avg: 1.23M 95% vs Avg 13.45 Day Range 13.88 11.09 52 Week Range 22.11 Partner Center Your Watchlists...Stock Price Forecast The 5 analysts offering 12-month price forecasts for Catalyst Pharmaceuticals Inc have a median target of 24.00, with a high estimate of 27.00 and a low estimate of...Catalyst Pharmaceuticals (CPRX) is a biopharmaceutical company that develops and commercializes therapies for rare diseases. The company's stock price, news, and analysis are based on its market cap, P/E ratio, dividend yield, and earnings growth. The consensus rating is Buy, with a price target of $24.75, an upside of 95.8%.For the current quarter, Catalyst is expected to post earnings of $0.21 per share, indicating a change of +133.3% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over ...Top Analysts Based on 3 analyst s offering 12 month price targets for Catalyst Pharmaceuticals Inc. Min Forecast $24.00 +68.9% Avg Forecast $25.00 +75.93% Max …For Catalyst Pharmaceuticals Stock (CPRX) price forecast for 2024, the average price target for Catalyst Pharmaceuticals Stock is $17.29 with a high forecast of $22.19 and a low forecast of $12.39. The average CPRX price prediction of 2024 represents a +31.36% increase from the last price of $13.16.Change. % Change. CPRX. Catalyst Pharmaceuticals, Inc. 12.71. -0.31. -2.38%. According to the average brokerage recommendation (ABR), one should invest in Catalyst (CPRX). It is debatable whether ...

Check price target & stock forecast for Catalyst here>>> While the ABR calls for buying Catalyst, it may not be wise to make an investment decision solely based on this information.

TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.com

About the IonQ Inc stock forecast. As of 2023 December 04, Monday current price of IONQ stock is 13.610$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception). IonQ stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given ...6 mar 2023 ... Catalyst Pharmaceuticals Inc. Common Stock, CPRX stock forecast, stock analysis, stock rating, stock news, share price, company information, ...Even after the latest disappointment, sell-side forecasts still call for dramatic improvement in this A-rated energy stock’s operating performance over the next few years.Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Stock Price Forecast. The 7 analysts offering 12-month price forecasts for VNET Group Inc have a median target of 4.33, with a high estimate of 8.12 and a low estimate of 2.59. The median estimate ...Nov 1, 2023 · Catalyst Pharmaceuticals, Inc. (CPRX) : Free Stock Analysis Report. ... The median home sale price will fall 1.7% next year after eking out an anticipated 0.2% gain in 2023, according to the forecast. CPRX Overview Stock Screener Earnings Calendar Sectors Nasdaq | CPRX U.S.: Nasdaq Catalyst Pharmaceuticals Inc. Watch list NEW Set a price target alert After Hours Last …Click here to find out why CPRX stock is rated as a buy. ... which adds further confidence towards achieving our FYCOMPA full year 2023 net product revenue forecast of $130 million. Adding FYCOMPA ...View the latest Catalyst Pharmaceuticals Inc. (CPRX) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Brokerage Recommendation Trends for CPRX. Check price target & stock forecast for Catalyst here>>> While the ABR calls for buying Catalyst, it may not be wise to make an investment decision solely ...The highest forecast stands at $28.00, while the lowest forecast is $14.00. Overall, the analyst rating consensus for ImmunoGen is a Strong Buy, based on the assessments of 8 Wall Street analysts. Examining ImmunoGen’s stock price history, it stood at $29.35 at the time of the report.Weather forecasts are essential tools for planning our daily activities, especially when it comes to the next 10 days. Understanding a weather 10 day forecast can help us make informed decisions about outdoor events, travel plans, or even w...Instagram:https://instagram. mvst stock forecastpe ratio for the sandp 500goodyear tires stockvalue 1943 d steel penny Catalyst Pharmaceuticals, Inc. (CPRX) : Free Stock Analysis Report. ... The median home sale price will fall 1.7% next year after eking out an anticipated 0.2% gain in 2023, according to the forecast. is ford a good stock to buyiog inc 7 brokerages have issued 12-month price targets for Cross Country Healthcare's shares. Their CCRN share price targets range from $21.00 to $40.00. On average, they anticipate the company's share price to reach $27.50 in the next year. This suggests a possible upside of 34.7% from the stock's current price.Mar 10, 2023 · Catalyst Pharmaceutical (CPRX Quick Quote CPRX - Free Report) is one of the stocks most watched by Zacks.com visitors lately.So, it might be a good idea to review some of the factors that might ... benzinga pro pricing The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction. The market is in highly overbought territory. Beware of a trend reversal. See More Share. CPRX Stock Quotes API . CPRX Related ETF s. Symbol %Holdings 3M %Chg; CPRX +1.52% : Catalyst Pharm Inc: IJR : 0.14% -1.76% : S&P ...Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business Every investor in Catalyst Pharmaceuticals, Inc. ( NASDAQ:CPRX ) should be aware of the most ...A share price of Catalyst Pharmaceuticals Inc [CPRX] is currently trading at $13.65, up 2.02%. An important factor to consider is whether the stock is rising or falling in short-term value. The CPRX shares have gain 8.85% over the last week, with a monthly amount drifted -0.15%, and not seem to be holding up well